Probiotics in Paget's disease
- Conditions
- Paget's disease of boneMusculoskeletal Diseases
- Registration Number
- ISRCTN12180483
- Lead Sponsor
- Accord (United Kingdom)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 75
1. Aged 18 years old and over
2. Clinical diagnosis of Paget's disease of the bone confirmed by characteristic appearances on radionuclide bone scan and /or x-ray
3. Serum total alkaline phosphatase elevated above the upper limit of normal or within the upper half of the local reference range
4. Willing and able to give informed consent
1. Unable or unwilling to give informed consent
2. Bisphosphonate therapy thought to be indicated for the treatment of Paget's disease of the bone on clinical grounds
3. Currently being treated with bisphosphonates, denosumab or calcitonin for any reason
4. Currently being treated with combined calcium and vitamin D supplements
5. Treatment with oral or intravenous bisphosphonates during the previous 24 months
6. Treatment with denosumab during the past 12 months
7. Treatment with calcitonin during the previous 3 months.
8. Treatment with combined calcium and vitamin D supplements during the past 4 weeks
9. Receiving probiotics during the previous 3 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method